KRAS and neoplasm: Using the KRAS mutant GC cell line (AGS) and the KRAS wild-type GC cell line (MKN-45), our data reveal that overexpression of FBXW2 exerts a tumor-suppressing role in both GC cell lines regardless of KRAS mutational status.